Create a narrative

Pharma Mar Community

BME:PHM Community

1 Narratives written by author
0 Comments on narratives written by author
31 Fair Values set on narratives written by author

Create a narrative

AN

AnalystConsensusTarget

Consensus Narrative from 5 Analysts

ZEPZELCA's EMA Submission Will Broaden Cancer Treatment Availability In Europe

Key Takeaways Successful approval of ZEPZELCA in Europe and new markets could significantly boost PharmaMar’s future revenues, leveraging positive trial results. PharmaMar's strong cash position and robust pipeline support reinvestment and potential long-term revenue growth, with a stable cost structure enhancing margins.

€98.60

FV

14.8% undervalued

37.86%

Revenue growth p.a.

0

0

15

7 days ago